Background : Cystic renal cell carcinoma has been reported to have a good prognosis. However, previous studies included cases of multilocular cystic renal cell carcinoma, which has an excellent prognosis, and renal cell carcinoma with cystic necrosis, which has an adverse prognosis. Therefore, we analyzed the prognostic influence of cystic change in clear cell renal cell carcinoma after excluding those morphological features. Methods : We identified 225 patients with clear cell renal cell carcinoma who underwent nephrectomy between 2001 and 2003. The clinicopathologic features were compared with clinical outcomes. Results : Cystic change in clear cell renal cell carcinoma (n = 66) was significantly associated with younger patient age (< 55), smaller tumor size (≤ 4 cm), lower pT stage (pT1, T2), M0 stage at initial diagnosis, lower tumor, node, and metastasis stage (I, II), and lower nuclear grade (1, 2). Patients with cystic change in clear cell renal cell carcinoma had significantly longer cancer-specific (p = 0.015) and progression-free survival (p = 0.004) than those without cystic change, by univariate analysis. Multivariate analysis revealed that cystic change significantly decreased the risk of cancer progression (risk ratio, 0.27; 95% confidence interval, 0.11 to 0.69). Conclusions : In patients with clear cell renal cell carcinoma, cystic change is a good independent predictor for survival.
The incidence of renal cancers has been increasing steadily with 57,760 new diagnoses and 12,980 deaths in the United States in 2009. 1 Renal cell carcinoma (RCC) accounts for approximately 75% of these cases 2 and clear cell type is the most common histologic variant. Clear cell RCC is associated with poorer cancer-specific survival (CSS) when compared with other subtypes. 3 However, multilocular cystic renal cell carcinoma (MCRCC), a distinct subtype of clear cell RCC, has excellent prognosis with a 5-year survival rate of 95% to 100%. [4] [5] [6] Some studies reported that patients with cystic RCC, a category that includes MCRCC, unilocular cystic RCC, RCC with extensive cystic necrosis, and cystic RCC characterized by a unilocular cyst with one or a few isolated mural tumor nodules, had a better prognosis than patients with solid clear cell RCC. [7] [8] [9] [10] [11] These studies should be clarified since RCC with cystic necrosis carries a significantly worse prognosis 12 and MCRCC has an excellent outcome. Therefore, we performed a retrospective analysis to assess the prognostic implication of cystic change in clear cell RCC after excluding those confounding factors.
MATERIALS AND METHODS

Patient selection
We reviewed the pathology slides of patients treated with rad- 14 MCRCC was defined as the tumor mass entirely composed of multilocular cysts lined by thin septa containing clear tumor cells, and with no expansile solid nodule (Fig. 1A) . Finally, the cases of 225 patients with clear cell RCC were examined for analysis.
Collection of clinicopathologic features
The clinical features included age at the time of surgery, sex and clinical outcomes. The duration of follow-up was calculated from the date of nephrectomy to the date of cancer progression (i.e., distant metastases after nephrectomy for the primary tumor), death, or last follow-up. The pathologic features evaluated included tumor size, tumor, node, and metastasis (TNM) stage according to the 2002 American Joint Committee on Cancer (AJCC), 15 regional lymph node involvement, distant metastases, nuclear grade according to the Fuhrman system, and cystic change. If no pathologic confirmation of metastatic disease was performed, patients were assessed for clinical metastatic stage on the basis of clinical examination and radiologic studies. Tumor size was measured according to the longest diameter. Nuclear grade was based on the highest-grade tumor area identified. A tumor was regarded as having cystic change when it was grossly cystic and the cyst walls were lined by clear tumor cells. Cysts were either multilocular or unilocular and there was at least one area of expansile tumor nodule, which differentiated the tumor from MCRCC. In addition, the cysts could not contain necrotic tumor tissue. Usually, the cystic area consisted of macrocysts in a multilocular pattern with the lumens containing serous fluid and erythrocytes (Fig. 1B) . Microscopic slides from all specimens were reviewed by two pathologists without knowledge of patient outcomes.
Statistical methods
Comparisons of clinical and pathologic features between clear cell RCC patients with and without cystic change were assessed using chi-square and Fisher exact tests. CSS was measured from the date of surgery to the date of cancer-related death or the last follow-up. Progression-free survival (PFS) was calculated from the date of surgery to the date of tumor recurrence/metastasis or the last follow-up. Survival analysis was performed using the Kaplan-Meier method and the results were compared by the logrank test. Multivariate analysis was performed using Cox proportional hazards regression models. Statistical analyses were performed using the SPSS ver. 17.0 (SPSS Inc., Chicago, IL, USA). All p-values of 0.05 or less were considered statistically significant.
RESULTS
The clinical and pathologic features for the 225 patients who underwent nephrectomy for clear cell RCC are summarized in Table 1 . The mean age at the time of surgery was 55 years (range, 28 to 82 years). The mean duration of follow-up was 59.96 months (median, 64.0 months; range, 2 to 97 months). Of the 225 patients, 45 (20%) patients died during the follow-up, with 33 (14.7%) dead of disease. One hundred and sixty-three (72.4%) patients were alive without evidence of RCC, and 17 (7.6%) patients were currently alive with evidence of disease. Grossly, the mean tumor size was 5.1 cm (range, 1 to 16 cm). One hundred and eleven (49.3%) patients had tumor masses greater than 4 cm in size.
Cystic change in clear cell RCC was observed in 66 (29.3%) patients (Table 1) . Its associations with clinicopathologic features are summarized in Table 2 . It was significantly associated with patient age less than 55 years old (p < 0.001), tumor size 4 cm or less (p = 0.029), less advanced primary tumor status (p = 0.035), absence of distant metastases at initial diagnosis (p = 0.04), lower TNM stage (p = 0.011), and lower Fuhrman nuclear grade (p = 0.038) ( Table 2 ).
Univariate analysis showed that patients with age younger than 55 years old (CSS, p = 0.001; PFS, p < 0.001), tumor size 4 cm or less (p < 0.001), less advanced primary tumor status (p < 0.001), absence of regional lymph node (p < 0.001), abscence of distant metastasis (p < 0.001), lower TNM stage (p < 0.001), and lower Fuhrman nuclear grade (p < 0.001) were significantly associated with longer CSS and PFS (Table 3) . Tumors with cystic change were also correlated with longer survival (CSS, p = 0.015; PFS, p = 0.004) (Fig. 2) .
Multivariate analysis determined the following independent prognostic factors for CSS as well as for PFS in this study, as follows: tumor size 4 cm or less (CSS, p = 0.032; PFS, p = 0.002), primary tumor status (CSS, p = 0.005; PFS, p = 0.005), regional lymph node status (CSS, p = 0.037; PFS, p = 0.013), distant 
DISCUSSION
Imaging studies reveal cystic changes in 4% to 15% of renal cell carcinomas. 16 In 1986, Hartman et al. 16 divided these tumors into 4 groups to explain their cystic nature: intrinsic multilocular growth, intrinsic unilocular growth, cystic necrosis, and origin from the epithelial lining of a pre-existing cyst. Several Table 3 . Univariate analysis of clinicopathologic factors in 225 patients with clear cell renal cell carcinoma authors have reported that such "cystic RCC" had a more favorable prognosis than noncystic RCC. 7-11 Bielsa et al. 7 and Webster et al. 11 demonstrated that survival was significantly longer in patients with cystic RCC. In these studies, some cases of cystic RCC with multilocular growth pattern might now be categorized as multilocular cystic RCC by the 2004 WHO classification of the renal tumors.
14 MCRCC is composed entirely of cysts of varying sizes lined by a single layer of neoplastic cells and without an expansile tumor nodule. It must be distinguished from conventional RCC with cystic change, since it has an extremely good prognosis 5 and currently is considered as a specific entity, "multilocular cystic renal neoplasm of low malignant potential". 17 Consequently, those previous studies may have overestimated the prognosis of patients with cystic RCC. Furthermore, some studies also included RCC with cystic necrosis and this could act as a confounding factor contributing to the underestimation of clinical outcome. Consequently, we excluded cases of MCRCC in the current study and did not consider areas of cystic necrosis as cystic change. This is the first study that statistically evaluated the prognostic impact of cystic change in clear cell RCC excluding cases with MCRCC and RCC with cystic necrosis.
The TNM staging system is the most studied and most accurate tool for predicting the prognosis of RCC. 18 Our study was in close agreement with the results of previous studies in spite of the relatively small population size. Because the outcomes of RCC can still be unpredictable, other prognostic factors and outcome prediction models have been studied. The current version of the TNM staging system uses a 4 cm cut-off value to distinguish between T1a and T1b RCC. Several authors have suggested different tumor size cut-off ranging from 4.5 cm to 5.5 cm.
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In this study, we adopted 4 cm as a tumor size breakpoint for stratifying the patients and showed that tumor sizes greater than 4 cm significantly increased the risk of cancer mortality (RR, 9.53; 95% CI, 1.21 to 74.90; p = 0.032) and progression (RR, 5.57; 95% CI, 1.89 to 16.42; p = 0.002) by multivariate analysis. Fuhrman nuclear grade has been shown to be of prognostic significance in series of mixed tumor types. 3, 20, 21 However, using 4-tiered system, it did not retain prognostic significance by multivariate analysis that included TNM stage. 20 On the other hand, significant differences in outcome were seen after separating patients with nuclear grade 1 and grade 2 tumors from patients with grade 3 and grade 4 tumors. 22 Our study also showed that nuclear grade maintained prognostic significance only after grouping patients into 2-tiered system (grade 1 and 2 vs grade 3 and 4). We demonstrated that cystic change in clear cell RCC was significantly associated with patient age younger than 55 years old and less aggressive properties as follows: tumor size 4 cm or less, less advanced primary tumor status, absence of distant metastases at initial diagnosis, lower TNM stage, and lower Fuhrman nuclear grade. By univariate analysis, cystic change was significantly associated with longer survival (CSS, p = 0.015) and less intensive disease progression (PFS, p = 0.004). After adjustment for tumor size, primary tumor status, regional lymph node status, distant metastasis, and Fuhrman nuclear grade, clear cell RCC with cystic change exhibited a significantly decreased likelihood of cancer progression (RR, 0.27; p = 0.006). Therefore, the presence of cystic architecture in clear cell RCC, when grossly detected and then microscopically confirmed, is a good independent predictor for cancer progression, even if the cystic portion is not large enough to diagnose multilocular cystic RCC. Additional studies with large population size are needed to clarify the definition of cystic change and to better understand its impact on cancer mortality.
In conclusion, clear cell RCC with cystic change was found to be significantly associated with more favorable clinicopathologic parameters than noncystic RCC. In addition, the presence of cystic architecture in clear cell RCC was identified as an independent predictor of PFS by multivariate analysis. Routine documentation of cystic change may be advisable during the pathologic assessment of RCC.
